Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 17;85(14):2673-2687.e8.
doi: 10.1016/j.molcel.2025.06.004. Epub 2025 Jun 26.

Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer

Affiliations

Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer

Shouhai Zhu et al. Mol Cell. .

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with deleterious BRCA1/2 alterations. Although this marks a significant milestone, intrinsic or acquired therapy resistance remains a major challenge that limits clinical efficacy. Here, we demonstrate that dysregulated ubiquitination and turnover by the cullin 3 (CUL3)ZBTB2 E3 ligase complex induce the upregulation of the short isoform of nuclear-receptor-binding SET domain protein 3 (NSD3) (NSD3S), which confers PARPi resistance in prostate cancer cells and patient-derived mCRPC samples. Mechanistically, ATR drives the localization of NSD3S at stalled replication forks, where it antagonizes the PTIP-dependent recruitment of the MRE11 nuclease, thereby protecting nascent DNA from extensive degradation and ensuring fork stabilization. Importantly, pharmacological degradation of NSD3S using an NSD3-targeting proteolysis-targeting chimera (PROTAC) efficiently enhances PARPi sensitivity in both cell-line-derived xenograft and patient-derived xenograft (PDX) mouse models. These findings establish NSD3S as a key determinant of PARPi toxicity in mCRPC.

Keywords: CUL3; MRE11; NSD3; PARP inhibitor; PTIP; prostate cancer; proteolysis-targeting chimera; replication fork.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

    1. Kulasegaran T, and Oliveira N (2024). Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management. Curr Treat Options Oncol 25, 914–931. 10.1007/s11864-024-01215-2. - DOI - PMC - PubMed
    1. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al. (2015). Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228. 10.1016/j.cell.2015.05.001. - DOI - PMC - PubMed
    1. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, et al. (2018). The long tail of oncogenic drivers in prostate cancer. Nat Genet 50, 645–651. 10.1038/s41588-018-0078-z. - DOI - PMC - PubMed
    1. Lord CJ, and Ashworth A (2017). PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152–1158. 10.1126/science.aam7344. - DOI - PMC - PubMed
    1. Ditonno F, Bianchi A, Malandra S, Porcaro AB, Fantinel E, Negrelli R, Ferro M, Milella M, Brunelli M, Autorino R, et al. (2024). PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence. Clin Genitourin Cancer 22, 402–412.e417. 10.1016/j.clgc.2023.12.011. - DOI - PubMed

MeSH terms

LinkOut - more resources